Austedo vs Qulipta
A side-by-side look at two neurology medications advertised on TV. Informational only — not medical advice.
| US Austedo | US Qulipta | |
|---|---|---|
| Generic name | deutetrabenazine | atogepant |
| Drug class | VMAT2 Inhibitor | CGRP Receptor Antagonist |
| Treats | Tardive dyskinesia, Huntington's chorea | Migraine prevention |
| Category | Neurology | Neurology |
| Manufacturer | Teva | AbbVie |
| Year approved | 2017 | 2021 |
| FDA warning | Black box warning | No boxed warning |
| Est. TV ad spend | $150M | $120M |
| Common side effects | Depression and suicidal thoughts (Huntington's), Drowsiness, Fatigue, Dry mouth | Nausea, Constipation, Fatigue, Decreased appetite |
Frequently asked questions
Is Austedo or Qulipta better?
Neither is universally "better." Austedo (deutetrabenazine) and Qulipta (atogepant) are both used for neurology, but the right choice depends on your medical history, insurance and your doctor's guidance. This comparison is informational only.
What's the difference between Austedo and Qulipta?
Austedo is a VMAT2 Inhibitor made by Teva, while Qulipta is a CGRP Receptor Antagonist made by AbbVie. See the table above for a side-by-side breakdown.
Which one spends more on TV ads?
Austedo has the larger estimated TV advertising budget of the two.